Introduction {#Sec1}
============

The neurotoxins from *Clostridium botulinum* and several related species represent some of the most lethal substances known \[[@CR1]--[@CR3]\]. The signs and symptoms include flaccid paralysis of the voluntary muscles, respiratory distress and death. The onset times and durations of paralysis depend on the serotype involved, the exposure route and the intoxicating dose. As summarized in \[[@CR4]\], the public is becoming increasingly aware of the roles of botulinum neurotoxins as food poisoning agents, as potential bioweapons \[[@CR1],[@CR2],[@CR5],[@CR6]\], and as approved treatments for various neurologic indications and other clinical uses \[[@CR7]\]. Significant resources \[[@CR8],[@CR9]\] have been devoted to the largescale production of heptavalent botulism antitoxin \[[@CR10]\]. Complementary research to engineer and develop high-affinity, monoclonal neutralizing antibodies is also being conducted \[[@CR11]\].

The bacteria express these toxins as single chain polypeptides (MW ∼150 kDa) which are later post-translationally modified to form two chains (heavy, 100kDa and light, 50 kDa) that are covalently linked by a disulfide bridge. The C-terminal half of the heavy chain specifically binds to extracellular acceptors at peripheral cholinergic nerve terminals \[[@CR12]\] that innervate striated and smooth muscles. A process resembling receptor-mediated endocytosis internalizes the toxin-bound receptor. As the intravesicular environment becomes acidic (pH 5), the N-terminal half of the heavy chain helps form cation-selective channels that may be involved in allowing the escape of the toxic moiety (presumably the catalytic light chain or its derivatives) into the neuroplasm (reviewed in \[[@CR13]\]). The toxic fragment is a zinc-dependent protease that cleaves at distinct sites and in a serotype-specific manner one or more of the SNARE proteins (SNAP-25, syntaxin and VAMP) involved in the synaptic vesicle-mediated release of acetylcholine. Once internalized, BoNT is no longer susceptible to circulating neutralizing antibodies or other impermeable inhibitors of its toxicity. This homologous family of proteins are grouped into seven immunologically distinct serotypes (BoNT/A-G) \[[@CR3],[@CR14]\]. SNAP-25 is cleaved by BoNT serotypes A, E and C1, syntaxin is cleaved by BoNT/C1, and VAMP is cleaved by the remaining BoNT serotypes \[[@CR14]\].

The present study was designed to extend a data-driven minimal model developed by Simpson \[[@CR15]\] that described the kinetics of botulinum neurotoxin serotype A (BoNT/A) at the neuromuscular junction (NMJ) in producing paralysis in vitro. This original deterministic model consisted of a sequence of reactions based on the known mechanism of BoNT/A action, namely, binding to specific receptors located at cholinergic nerve terminals, translocating into the neuroplasm and, in turn, exerting a toxic effect. All three steps were separately examined experimentally and quantitatively characterized by apparent first-order reaction rates. Modifications were introduced in our study to allow for the changes in paralysis time course seen under different in vivo conditions \[[@CR16]--[@CR18]\]. We also developed a quantitative relationship between the onset rate of paralysis and the time that is available to neutralizing antitoxins or other non-permeable countermeasures to exert some inhibitory effect.

Methods {#Sec2}
=======

Reaction rates and other rate constants {#Sec3}
---------------------------------------

The experimentally measured reaction rate of BoNT/A binding to the in vitro NMJ preparation model was compared to previously determined association and dissociation (on and off) rate constants reported in \[[@CR19]\] for rat brain synaptosomes. These microscopic rate constants were adjusted for a ∼20°C difference in temperature because the NMJ experiments were conducted at 35°C and the synaptosomal studies were performed at 4°C. The experimentally determined value for the temperature coefficient, Q~10~, for the binding step was used as the multiplicative factor by which a rate constant is increased when increasing the temperature by 10°C \[[@CR20]\]. It was assumed that the measured Q~10~ value was a constant for this 20°C range of temperatures, that a steady state of equilibrium was achieved and that toxin was not internalized following binding.

Reaction equations: 3-Step Model {#Sec4}
--------------------------------

The present models for the receptor binding, the nerve-terminal entry and the subsequent toxic (lytic) activity of BoNT/A were developed using the same general reaction schemes and numerical procedures that were previously used for modeling the kinetics of neurotransmission at peripheral and central synapses \[[@CR21],[@CR22]\]. Reactions describing the 3-step model were derived from \[[@CR15]\] for BoNT/A intoxication at the in vitro rat NMJ: $$\documentclass[12pt]{minimal}
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$$free\buildrel {{k_B}} \over \longrightarrow bound\buildrel {{k_T}} \over \longrightarrow trans\buildrel {{k_L}} \over \longrightarrow lytic$$
\end{document}$$ where the system of coupled first-order differential equations is: $$\documentclass[12pt]{minimal}
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$$d\left[ {free} \right]/dt = - {k_B}\left[ {free} \right]$$
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$$d\left[ {bound} \right]/dt = {k_B}\left[ {free} \right] - {k_T}\left[ {bound} \right]$$
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$$d\left[ {trans} \right]/dt = {k_T}\left[ {bound} \right] - {k_L}\left[ {trans} \right]$$
\end{document}$$$$\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$$d\left[ {lytic} \right]/dt = {k_L}\left[ {trans} \right]$$
\end{document}$$.

This 3-step model represents a minimal version of the original model for a free amount of neurotoxin to bind, translocate into the neuroplasm and generate lytic activity \[[@CR15]\]. Each species of BoNT/A is associated with a different environment: extracellular in solution (free), on the surface, bound to a receptor (bound), intracellular endocytotic vesicle (trans), and intracellular neuroplasm (lytic). The three irreversible steps eventually lead to the blockade of vesicle-mediated neurotransmission and the development of completemuscle paralysis in theNMJ experiments \[[@CR15]\]. The binding step implicitly contains diffusion of free BoNT/A (0.1 nM) to its binding sites at synaptic termini. The bound toxin undergoes translocation into the neuroplasm. Intracellularly, the toxic moiety exerts it enzymatic proteolytic activity on SNAP-25 \[[@CR14]\]. Embedded in this species is the paralysis that occurs postsynaptically. Rates of reaction were taken from \[[@CR15]\] where *k*~*B*~ = 0.058 min^−1^, *k*~*T*~ = 0.141 min^−1^ and *k*~*L*~ = 0.013 min^−1^. This minimal 3-step scheme is a simplification from \[[@CR15]\] because it omits three unknown parameters representing binding sites for each species of toxin. An analytic expression derived for the lytic species, $$\documentclass[12pt]{minimal}
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\end{document}$$, was used to verify the selection of the time steps for the numerical solution and to establish further confidence in our minimal approach. \[*T* \]~*tot*~ represents the total normalized amount of toxin. Analytic expressions for the other species are available from the Electronic Supplementary Material.

Reaction equations: 4-Step Model {#Sec5}
--------------------------------

The 4-step model is an extension of the 3-step model. BoNT/A is present at t=0 in the bulk solution (S) and the rate constant, *k*~*S*~, simulates the rate of movement of the non-binding species of BoNT/A from the bulk medium to the extracellular solution that surrounds the nerve termini: $$\documentclass[12pt]{minimal}
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$$d\left[ {free} \right]/dt = {k_S}\left[ <Emphasis Type="BoldUnderline">lk</Emphasis> \right] - {k_B}\left[ {free} \right]$$
\end{document}$$.

In the 3-step model, initial conditions (t=0) for the normalized molecular species of BoNT were \[*free*\]=1.0, \[*bound*\]=0 and \[*lytic*\]=0, while in the 4-step model these species were initially set to zero and the \[*bulk*\]=1.0. As in the 3-stepmodel, an analytic expression was derived for the lytic species: $$\documentclass[12pt]{minimal}
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Analytic expressions for the other species in this model are available from the Electronic Supplementary Material. Values of *k*~*S*~ were systematically changed from 0.0001 to 15 min^−1^. In these models of in vivo systems there is no explicit clearance (i.e., loss of toxin from those systems), only an implicit one that is embedded in the k~*S*~ rate value. It was assumed that the amount of BoNT that was injected intramuscularly became distributed in the extra-vascular space, and was partially taken up by the circulatory system or in various organs (e.g., liver, spleen, kidney) as has been demonstrated in \[[@CR4]\] following i.v. injections of BoNT. The kinetic parameters used in these minimal models are tabulated at <http://botdb.abcc.ncifcrf.gov>.

Diaphragm muscle function (peak twitch amplitude induced by electrical stimulation of the phrenic nerve) was defined as the normalized amount of tension remaining after the formation of the lytic species: $$\documentclass[12pt]{minimal}
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$${\rm{tension}} = 1.0 - \left[ {lytic} \right]$$
\end{document}$$.

Values of t~10~ are the times at which the model predicts that the peak twitch tension is 10% of the maximum tension, i.e., a 90% reduction in tension. This level of residual tension was used in these in vitro experiments because complete paralysis is difficult to accurately measure \[[@CR15]\]. The twitch responses were measured after exposure to 300 ng (10^−10^ M) BoNT/A in 20 ml bathing chambers as in previous in vitro NMJ studies \[[@CR23]\]. Nerve-muscle preparations were exposed to toxin-containing media that were made with 0.5mM Ca^2+^ and 5.0mM Mg^2+^ to prevent toxin internalization. After a 60 min incubation, the preparations were washed with saline then soaked in control medium.

Other response measures were used in the mouse in vivo studies \[[@CR7],[@CR17]\] and in clinical studies \[[@CR18]\]. In \[[@CR7]\], time spent by mice on an exercise wheel was monitored during the onset and recovery of the BoNT/A-induced paralysis (0.2--1.5 ng). The study in \[[@CR17]\] measured toe abduction reflexes as the functional parameter affected by the i.m. injection of ∼26 ng of BoNT/A. In the clinical study \[[@CR18]\], the patient reported the alleviation of subjective symptoms of cervical dystonia following i.m. injections of BoNT/A which are 1--4 ng according to \[[@CR24]\] for this neurologic disorder. In all of the simulations using these in vivo data, the term "response" replaces "tension" in Eq. [3](#Equ3){ref-type=""}.

In this study, we estimated the upper limit of time that non-permeable inhibitors of BoNT/A (e.g., an antibody) have some effect. The value of this available time (t~inhib~) was operationally defined as the time at which the amount of unbound BoNT/A is at least 10% of the initial unbound species. We are using this metric from the point of viewthat it is the toxin that needs to be inhibited by an antibody or other non-permeable inhibitor. Because t~inhib~ is quantitative, it can be later refined when the time course of the unbound amount of BoNT/A is experimentally resolved. In the 3-step model, the relative value of the unbound BoNT/A is equal to the value of the free species, while in the 4-step model, the relative value of the unbound BoNT/A is equal to the sum of the values of the free and the bulk species.

Computer programs and statistical methods {#Sec6}
-----------------------------------------

The kinetic schemes were visually constructed and edited interactively using JDesigner which is part of the open source Systems Biology Workbench (SBW) \[[@CR25]\]. This program saves models in SBML format so that they can be used as a front-end software component to any SBW-compatible equation solver. The ordinary first-order differential equations describing the reactions built with JDesigner were solved by Jarnac, a script language-based program for analyzing biochemical reaction networks \[[@CR25]\]. Mathematica®(Wolfram Research Inc, Champaign, Illinois) generated analytic expressions that were used to verify the selection of the time steps for the numerical solutions by Jarnac and to establish further confidence in our minimal approach. A spreadsheet-compatible data-analysis utility was used to digitize and store two dimensional coordinates of data points from selected figures shown in \[[@CR4],[@CR7],[@CR15]--[@CR17]\] and \[[@CR18]\] (Datatrend Software, Raleigh, North Carolina). Linear regression analysis of the form y=y~0~ +ax was performed on the data in Fig. [2](#Fig2){ref-type="fig"} to calculate coefficients of determination (R^2^) and values of the slope (a) and intercept (y~0~) along with standard errors of the mean (S.E.M.) using SigmaPlot (ver. 9.01, 2004, Systat Software, Inc., Chicago, Illinois). Area under the curve (AUC) calculations were performed on the numerical outputs (Fig. [1](#Fig1){ref-type="fig"}) by summing the amount of free toxin (ng units) present at each time increment (60min) in the 3-step model. Because of the small amount of free toxin predicted for the simulation in Fig. [4](#Fig4){ref-type="fig"}, only the amount of bulk toxin was summed at each time increment (1 min) in the 4-step model. Elimination rates of the unbound (i.e., free or bulk) toxin species were calculated by taking the amount (ng units) at t=0 and dividing by the AUC value (min-ng units). Fig. 2Different values of *k*~*L*~ in the 3-step model simulated the frequency-dependence of the rate of onset of BoNT/A-induced paralytic activity. Panel A: plot of data points where values for t~10~ are expressed as normalized values. Panel B: The 3-step model (dashed line) produced a non-linear relation between *k*~*L*~ (0.01 − 0.3min^−1^) and the time-to-10% tension, t~10~. Within the range of experimental data, the plot was linear and at higher values of *k*~*L*~ approached an asymptotic value for the normalized values of t~10~. Panel C: Values of *k*~*L*~ were adjusted to simulate normalized t~10~ values at each of the four experimentally used nerve stimulation frequencies. Circles: experimental data from Fig. [4](#Fig4){ref-type="fig"} in \[[@CR15]\]; lines in Panels A and C: least-squares fits drawn through the data pointsFig. 1Simulation of experimental NMJ data with the 3-step model. The time courses of the model species can be compared with the development of BoNT/A-induced paralysis (filled symbols, data from \[[@CR15]\]). The time-to-10% tension, t~10~, was 204 min. The upper limit for the amount of time available for an inhibitor of BoNT/A to exert some effect, tinhib, was ⩽40 min (see Methods). All BoNT/A species are represented as relative values. Dotted line: free BoNT/A; long dashes: bound toxin; short dashes: translocated species; black line: amplitudes of peak twitch tension numerically calculated from the 3-step model; white line (superimposed on black line): amplitudes of peak twitch tension calculated from Eq. [1e](#Equ1e){ref-type=""}Fig. 4Time-dependence of the BoNT/A species from the 4-step model that simulated the clinical data. The time courses of the different species can be compared with the relatively slow loss of tension (t~10~ =15,450 min or 106 days) of BoNT/A-induced paralysis. In contrast to the in vitro NMJ (Fig. [1](#Fig1){ref-type="fig"}), the time courses of the unbound BoNT/A and the lytic species overlapped, making the estimated upper limit value of t~*inhib*~ longer in vivo than at the isolated NMJ. Closed circles: subjective clinical data from \[[@CR18]\]; black line: responses were calculated numerically from the 4-step model using k*S* = 0.00015 min^−1^; white line: responses were calculated from Eq. [2c](#Equ2c){ref-type=""}

Results {#Sec7}
=======

Relating the binding reaction rate to the receptor binding and dissociation rate constants for BoNT/A {#Sec8}
-----------------------------------------------------------------------------------------------------

Before examining the 3-step model, we tested the hypothesis that the receptors for BoNT/A are not saturated at 0.1nM, the concentration used in \[[@CR15]\]. In addition, we evaluated the relation between the measured apparent first-order binding reaction at the rat NMJ (*k*~*B*~) \[[@CR15]\] and the association (*k*~*on*~) and dissociation (*k*~*off*~ ) microscopic rate constants that have been measured using rat cerebrocortical-derived, synaptosome preparations \[[@CR19]\]. The values for *k*~*on*~ = 0.0138 nM^−1^ min^−1^ and *k*~*off*~ = 0.0072 min^−1^ at 4°C \[[@CR19]\] correspond to a *K*~*d*~ = 0.52nM. \[[@CR15]\] the rate of paralysis in the rat NMJ preparation (*k*~*B*~ = 0.058 min^−1^ was measured under conditions of low \[Ca^2+^\], high \[Mg^2+^\] containing solutions at 35--36°C to block the internalization step (Fig. [2](#Fig2){ref-type="fig"} of \[[@CR15]\])). In keeping with experimental observations \[[@CR15]\], itwas assumed that low\[Ca^2+^\], high \[Mg^2+^\]-containing solutions did not affect these on and off rate constants in this reversible reaction: $$\documentclass[12pt]{minimal}
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$$U + RB$$
\end{document}$$ where \[*U*\] = \[BoNT/A\](unbound), \[*R*\] = binding site (productive ecto-acceptor) \[[@CR26]\], and \[*B*\] = \[BoNT/A\](bound). Using the experimentally determined value for Q~10~ = 1.6 for the binding step \[[@CR15]\], the temperature-adjusted values for *k*~*on*~ and *k*~*off*~ at 35°C were estimated to be 0.056nM^−1^ min^−1^ and 0.029 min^−1^, respectively, and are used in the equations below. The total toxin and binding site concentrations at t \> 0 are $$\documentclass[12pt]{minimal}
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$${\left[ T \right]_{tot}} = \left[ U \right] + \left[ B \right];{\left[ R \right]_{tot}} = \left[ R \right] + \left[ B \right]$$
\end{document}$$.

The binding-site occupancy was assumed to be described by the mass-law formulation to give an equilibrium dissociation constant $$\documentclass[12pt]{minimal}
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$${K_d} = {{{k_{off}}} \over {{k_{on}}}} = {{\left[ U \right]\left[ R \right]} \over {\left[ B \right]}}$$
\end{document}$$ in which the species concentrations are substituted for their activities. These terms are related to the experimentally measured value for *k*~*B*~, an apparent first-order rate constant, that is the reciprocal of the relaxation time constant (τ) for a reversible, single-step bimolecular reaction \[[@CR27]\]: $$\documentclass[12pt]{minimal}
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$${k_B} = 1/\tau = \left( {{{\left[ T \right]}_{tot}} + {{\left[ R \right]}_{tot}}} \right){k_{on}} + {k_{off}}$$
\end{document}$$

Combining and rearranging Eqs. [4](#Equ4){ref-type=""}--[6](#Equ6){ref-type=""} yields a quadratic expression $$\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$$\eqalign{ & {k_B} = 1/\tau = \left( {{{\left[ T \right]}_{tot}} + {{\left[ R \right]}_{tot}}} \right){k_{on}} + {k_{off}} \cr & {\left[ R \right]^2} + \left\{ {2{K_d} - {k_B}/{k_{on}}} \right\}\left[ R \right] + \left( {{K_d}{{\left[ T \right]}_{tot}} - {K_d}{K_B}/{k_{on}} + K_d^2} \right) = 0 \cr} $$
\end{document}$$ in which the positive root of \[*R*\] is: $$\documentclass[12pt]{minimal}
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$$\left[ R \right] = {{ - \left\{ {2{K_d} - {k_B}/{k_{on}}} \right\} + \sqrt {{{\left\{ {2{K_d} - {k_B}/{k_{on}})} \right\}}^2} + 4\left\{ {{K_d}{{\left[ T \right]}_{tot}} - {K_d}{k_B}/{k_{on}} + K_d^2} \right\}} } \over 2}$$
\end{document}$$

Solving for \[*R*\] allows values for \[*U*\] and \[*B*\] to be calculated $$\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$$\left[ U \right] = {{\left( {{{\left[ T \right]}_{tot}}/{K_d}} \right)} \over {\left[ R \right] + \left( {1/{K_d}} \right)}}$$
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$$\left[ B \right] = {\left[ T \right]_{tot}} - \left[ U \right]$$
\end{document}$$.

Using this approach with a dimensionless value of T~tot~ =1.0, the values for the reaction species at 35°C (assuming a steady state of equilibrium and no toxin internalization) were calculated to be \[*R*\]=8.6, \[*U*\]=0.69 and \[*B*\]=0.31. From these results, the values of *K*~*d*~ and the corresponding on and off rate constants support the idea that the binding sites for BoNT/A are not saturated. These results also support the hypothesis that the binding reaction rate for BoNT/A measured in the isolated NMJ at 35--36°C can be feasibly compared with the microscopic on/off rate constants for BoNT/A measured in rat brain at 4°C.

The 3-step model: estimates of tinhib and the frequency dependence of toxicity at the NMJ {#Sec9}
-----------------------------------------------------------------------------------------

As depicted in Fig. [1](#Fig1){ref-type="fig"}, the experimental data collected from the in vitro NMJ (adapted from Fig. [4](#Fig4){ref-type="fig"} of \[[@CR15]\]) was simulated with a minimal 3-step model. In those experiments, BoNT/Awas incubated in low-Ca^2+^, high-Mg^2+^ containing-media for 40 min to allow near-maximal binding. A second incubation period with normal media allowed for near-maximal translocation (∼90% in 16 min) which was followed by the commencement of phrenic nerve stimulation to monitor the gradual decline in twitch tension. In contrast, BoNT/A was applied in this and the 4-step model at t=0. The time courses of the four BoNT/A species can be visually compared during the development of BoNT/A-induced paralysis (time-to-10% tension, t~10~=204 min). The numerical solution generated by Jarnac for the tension curve using a time step of 1 min (Fig. [1](#Fig1){ref-type="fig"}, black line) was verified with an analytic expression (white curve superimposed on black line, Eqs. [1e](#Equ1e){ref-type=""} and [3](#Equ3){ref-type=""}). The time course of the free BoNT/A species provides a quantitative metric for estimating the time available for an inhibitor to exert some effect (t~inhib~), as defined in the Methods. In this 3-step model, t~10~ was predicted to be five times longer than t~inhib~. This model predicted that to exert some degree of inhibition, impermeable neutralizing antibodies or BoNT/A inhibitors need to be applied within 40 min of the addition of 0.1nM BoNT/A to the bathing chamber, i.e., before a ∼20% reduction of nerve-evoked twitch tension occurs.

The use-dependence associated with BoNT/A at the NMJ (data adapted from Fig. [5](#Fig5){ref-type="fig"} of \[[@CR15]\]) is illustrated in Fig. [2A](#Fig2){ref-type="fig"} in which paralysis times decreased (smaller values of t~10~) as the frequency of stimulating the phrenic nerve increased. Results of the linear regression analysis (see Methods) were: $$\documentclass[12pt]{minimal}
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$${t_{10}} = 94.6(5.4,{\rm{ S}}{\rm{.E}}{\rm{.M}}) - 85.4(35.9,{\rm{ S}}{\rm{.E}}{\rm{.M}}{\rm{.}})frequency{\rm{ }}({R^2} = 0.73)$$
\end{document}$$. Fig. 5Effects of varying *k*~*S*~ on the upper-limit estimates of tinhib and onset times for BoNT/A-induced paralysis. Panel A: the two durations, the times-to-10% peak tension (t~10~) and the tinhib, increase and converge as the values of *k*~*S*~ decrease. Panel B: the predicted concentration of unbound BoNT/A (decomposed into bulk and free species) at t~inhib~, is dependent on the value of *k*~*S*~. The placement of symbols along the *x*-axis in both panels (upward triangles, downward triangles, stars, and circles) are defined in Fig. [3](#Fig3){ref-type="fig"} and depict which of the unbound species and values of *k*~*S*~ are associated with those simulations. For clarity, these symbols were placed just above the *x*-axis to correspond with the appropriate values of k~*S*~

Changing the values of either *k*~*B*~ or *k*~*T*~ could only partially simulate the experimental data. In contrast, altering the values for the third reaction rate (*k*~*L*~) could, for the first time to our knowledge, simulate the entire set of data associated with the frequency-dependent enhancement of BoNT/A-induced paralysis. Values for t~10~ (Fig. [2B](#Fig2){ref-type="fig"}) overlap with the experimental data points that reside within a linear portion of the predicted non-linear relation between values of *k*~*L*~ and normalized times-to-10% tension. The values of *k*~*L*~ (0.013--0.019 min^−1^) correspond to values of stimulation frequencies that are within practical experimental limits (Fig. [2C](#Fig2){ref-type="fig"}): $$\documentclass[12pt]{minimal}
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The 4-step model: in vitro NMJ versus in vivo systems and estimates for t~inhib~ {#Sec10}
--------------------------------------------------------------------------------

Altering the three original reaction rates (*k*~*B*~, *k*~*T*~ and *k*~*L*~) failed to produce the slower onset rates of BoNT/A-induced paralysis observed in vivo. Thus, the 3-step model examined above was extended and used to simulate BoNT/A-induced responses of patients when administered as an approved therapeutic product \[[@CR18]\] and of mice when injected as a local paralysant \[[@CR7],[@CR17]\]. In this model, a new, initial reaction rate (*k*~*S*~) was created that represents the movement of BoNT/A (bulk species) from distal locations from its receptors to the proximal volume where the BoNT/A (free species) is available for binding.

Slow onset kinetics for the beneficial effects of treatments using BoNT/A have been published in the clinical literature. Normalized clinical data represented in Fig. [3](#Fig3){ref-type="fig"} are from a patient with cervical-dystonia-related complaints receiving BoNT/A intramuscularly (data from Fig. [1](#Fig1){ref-type="fig"}, injection series 1 in \[[@CR18]\]). Starting at approximately day 11, the maximum relief from symptoms was noted by the patient (t~10~= 10.6 days). The rate constant *k*~*S*~ was systematically varied from 0.0001 to 10 min^−1^ to provide an estimated value of 0.00015 min^−1^ for this model. Fig. 3Different values of *k*~*S*~ in the 4-step model simulated the onset of BoNT/A-induced effects in a variety of in vitro and in vivo data sets. The onset of paralysis with bath-applied BoNT/A at the rat NMJ (circles, from Fig. [1](#Fig1){ref-type="fig"}) is rapid and is associated with *k*~*S*~ values ⩾0.01 min^−1^. In vivo data (time using an exercise wheel, see Methods) from locally injected mice (stars, data from \[[@CR17]\]; upward triangles, data from \[[@CR7]\]) were simulated using *kS* =0.001 min^−1^. Clinical data (subjective measure of relief of neurologic symptoms, see Methods; downward triangles) are from a patient whose first session of BoNT/A treatment was on day 0 (data from \[[@CR18]\]). The maximum BoNT/A-induced effect, achieved by day 11, was simulated with *k*~*S*~ =0.00015 min^−1^

Other examples from two separate experimental studies usingmice are also included in Fig. [3](#Fig3){ref-type="fig"} \[[@CR7],[@CR17]\]. Both sets of data following local intramuscular injections could be simulated (*k*~*S*~ = 0.001 min^−1^). These data show a more rapid onset than the clinical data but are slower than the onset of paralysis seen with the in vitro rat NMJ data (see also Fig. [1](#Fig1){ref-type="fig"}). In this 4-step model, the NMJ data could be simulated with values of *k*~*S*~ ⩾ 0.01 min^−1^.

A comparison was also made of the time courses for the different toxin species in the 3-step model for the NMJ and the 4-step model for the in vivo data examined here. As for the model tension prediction in Fig. [1](#Fig1){ref-type="fig"}, the numerical solution for the tension curve (Fig. [4](#Fig4){ref-type="fig"}, black line) was verified analytically (Fig. [4](#Fig4){ref-type="fig"}; white curve, Eqs. [2c](#Equ2c){ref-type=""} and [3](#Equ3){ref-type=""}). As mentioned above, the 3-step NMJ model predicted that the time-to-10% tension (t~10~) was 5 times slower than t~inhib~. In contrast, the clinical data had a much slower onset (t~10~ = 15, 450 min or 10.6 days) for the BoNT-induced response, whose value was almost identical to that of t~inhib~ (Fig. [4](#Fig4){ref-type="fig"}). In this case, unbound BoNT/A was composed largely of the bulk species with a negligible presence of the free BoNT/A species. Thus, in the 4-step model for the clinical data, the time course of the unbound BoNT/A species was predicted to develop at essentially the same rate as the time course of paralysis.

The area under the curve (AUC) calculations were done to compare the temporal profiles of the unbound species of BoNT using in vitro NMJ and in vivo human data. The areas for unbound BoNT/A are about the same (\<20% difference) for the isolated NMJ and for the in vivo injections in man. The NMJ was exposed to 300 ng while the patient received an i.m. injection of approximately 1 ng BoNT/A. The amount of unbound BoNT at the NMJ decreased by 95% in 50 min. In man, the same decrease occurred in about 20,000 min (400 times longer). The AUC for the NMJ is 5174 min-ng using the 4-step model with k~*S*~ \> 0.01 min^−1^, while the AUC for man is 6406 minng using the 4-step model with k~*S*~ = 0.00015 min^−1^. As the value of k~*S*~ decreased, the amount of the unbound BoNT at any time point increased. Given the presumed differences in toxin purities and the uncertainty in the amount the patient received, these area values are remarkably similar. The rate of disappearance of the unbound BoNT/A is 400 times faster at the NMJ but this preparation also received about 300 times more BoNT/A than the patient. Thus, the calculated areas are similar due to offsetting differences in these rates and the amounts of toxin used.

To demonstrate the relation between the upper-limit estimate for t~inhib~ and timeto-10% tension (t~10~), the values of *k*~*S*~ were varied (Fig. [5](#Fig5){ref-type="fig"}). The symbols in this figure are the same as in Fig. [3](#Fig3){ref-type="fig"} for representing *k*~*S*~ values from the NMJ, from the i.m. injections in mice and from the clinical data. The 4-step model predicted that as *k*~*S*~ decreased, the absolute values for t~10~ and t~inhib~ increased. The relations between *k*~*S*~ and the upper-limit estimates of t~inhib~ and times-to-10% tension were non-linear (Fig. [5A](#Fig5){ref-type="fig"}). The largest component of the unbound BoNT/A species was predicted to be the bulk species for the data from the mouse local injections and from the clinical data where *k*~*S*~ ≤ 0.001 min^−1^. These calibration curves also provide upper-limit estimates for t~inhib~ that can be directly related to the duration for which a pre-defined threshold of tension is sustained. The plots in Fig. [5B](#Fig5){ref-type="fig"} over a range of values of *k*~*S*~ show the relative, decomposed values for unbound BoNT/A at t~inhib~ for the bulk and free species. The same trends were obtained with this model at other levels of post-exposure tension (50 and 90%) that were examined (data not shown).

Discussion {#Sec11}
==========

The results of this study support the hypothesis that a minimal approach can model responses from in vitro and in vivo systems. This common tactic of using a reductionist approach was applied because computing the BoNT/A-induced perturbations in nerve-evoked muscle twitches is beyond the practicality of developing fully detailed models of the mechanisms of neurotoxin action upon vesicle-mediated chemical neurotransmission. Several implicit assumptions were made in the two models examined. Most importantly, it was assumed for computational convenience that the models were independent of compartments and that uniform distributions existed for all the BoNT/A species and binding sites. Despite these simplifications and our incomplete knowledge of cellular structures, relevant results emerged using biochemical observables as guides, specifically, the binding reaction rate \[[@CR15]\] together with the microscopic binding and dissociation rate constants \[[@CR19]\]. These values were consistent with classic methods in ligand-binding studies in which the inequality \[*R*\]~tot~ \> \[*T* \]~tot~ is assumed to exist within a well-stirred system that is far from a state of binding-site saturation \[[@CR28]\]. Our calculations also show that various types of binding data from different tissues (central and peripheral neurons) and temperatures (4 to 35--36°) are related.

More insights were gained using the minimal models about the temporal relations between the extent of paralysis and the time that is available for an inhibitor to exert some effect, t~inhib~, under different in vitro and in vivo conditions. These simulations predicted upper-limit estimates for t~inhib~ during which 10% of the maximum amount of the unbound BoNT/A species is available for interacting with impermeable antagonists. Perhaps the most important concept to emerge from these minimal models is that as the onset rate of paralysis becomes slower, i.e., as the value of *k*~*S*~ decreases, it also becomes a better indicator of the upper-limit for when t~inhib~ and the times-to-10% tension (t~10~) converge (Fig. [5](#Fig5){ref-type="fig"}). The value of t~inhib~ is not a static amount of time but, rather, depends on the rate of paralysis onset.

These modeling results are related to a recent study of iatrogenic botulism. The existence of detectable serum levels of BoNT/A (12--24 mouse LD~50~) in three out of four case-patients 2--3 days following extremely high i.m. doses (up to eight million mouse LD~50~) of research-grade toxin \[[@CR29]\] suggests that the anti-toxin administration may have had a beneficial effect. These results also suggest that further development of animal models need to be conducted in vivo to test hypotheses that use onset rates of paralysis to obtain accurate estimates of t~inhib~ for neutralizing antibodies or impermeable, low molecular weight inhibitors.

The binding step for BoNT/A was intentionally simplified because of the inherent complexity of the intoxication process and of the variety of reactions comprising neurotransmission. At least two molecular components form the functional binding site for BoNT/A, a protein and a ganglioside \[[@CR14]\]. The ganglioside is GT1b or a related derivative \[[@CR30],[@CR31]\]. Although the protein component (SV2, synaptic vesicle protein-2) has twelve putative transmembrane spanning regions \[[@CR32],[@CR33]\], the location of the BoNT/A binding site is on a region of SV2 that is within a synaptic vesicle. This location implies that the interior solution of this structure must be in transient contact with the extracellular medium so that BoNT/A can bind immediately or bind following vesicle-pore closure and vesicle fission from the presynaptic membrane. During quiescent periods, the majority of the BoNT/A SV2 binding sites are not in contact with the extracellular medium and are unavailable for binding.

In contrast, with neural stimulation, these sites become exposed and available for binding, and as the frequency of stimulation increases, the time-to-10% tension (t~10~) decreases \[[@CR15]\] (Fig. [2](#Fig2){ref-type="fig"}). Although alterations in the other two reaction rates, by themselves, were insufficient to simulate the examined data, changes in all three of these reaction rates may be required to accurately model the experimental data. Thus, the enhanced rate of paralysis onset with increased nerve stimulation frequency may be a complicated function of enhanced calcium entry and an enhanced lytic effect, i.e., the proteolysis of the BoNT/A substrate SNAP25.

Other simplifications of the binding process in the 4-step model involve the initial step associated with the reaction rate, *k*~*S*~. As noted in \[[@CR15]\], there are anatomical and perhaps other barriers that interfere with BoNT/A readily diffusing to BoNT/A binding sites in the isolated NMJ. For the simulations of both the short-term in vitro and longer-term in vivo systems, delays in diffusion to binding sites caused by nonspecific binding \[[@CR26],[@CR34]\] also need to be considered. Potential non-specific binders of BoNT/A include serum proteins (e.g., albumin) \[[@CR4]\] and extracellularly located sites in the circulatory system.

Regarding the final two steps in the minimal models, simplifications were made for the translocation and lytic (toxic) processes \[[@CR13],[@CR15],[@CR35],[@CR36]\]. The translocation step can be decomposed into at least a dozen steps, the most prominent being vesicle fission from the plasma membrane into the neuroplasm, the activation of energy-dependent proton pumps with the subsequent decrease in intra-vesicular pH, the resultant conformational changes to BoNT/A, the reduction of its inter-chain disulfide bridge, the ion channel formation by the toxin's heavy chain, and the escape of the toxic moiety (presumably the 50kD light chain) into the neuroplasm where it exerts its toxic effect. A simplified single-step reaction is justified because the rates associated with many of these reactions are, as yet, undetermined.

The simplified lytic process includes among its most important reactions the zincdependent enzymatic activity of BoNT/A \[[@CR15]\] that can be described by Michaelis-Menten kinetics to cleave SNAP-25 \[[@CR37]\]. This proteolysis prevents the formation of a functional SNARE protein complex (including synaptobrevin, syntaxin and other proteins) to block the release of acetylcholine and eventually block stimulus-evoked muscle contractions. The lytic step also contains a steep non-linear relation between the amount of substrate cleaved and the decrease of the evoked muscle twitch amplitude \[[@CR38]--[@CR40]\].

Although we selected a clinical study that had an abundance of relevant quantitative data \[[@CR18]\], other clinical cases involving onset time scales of days should also be computationally examined and compared. For example, regarding cases of food-borne \[[@CR41]\], iatrogenic and wound botulism \[[@CR42]\] there is a lack of extensive clinical data sets in the publicly available literature and other open sources to archive paralysis time courses for future studies evaluating the temporal dependence of treatment effectiveness.

Notwithstanding the limitations of our minimal models, they have allowed us to simulate the onset kinetics of BoNT/A-induced effects observed in experimental and clinical studies. Beyond gaining a better appreciation of the temporal events that underlie the harmful as well as potentially beneficial effects of this family of neurotoxins, these models also provide us with an initial, quantitative framework for making extrapolations from animal model to human data.
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BoNT/A

:   Botulinum neurotoxin type A

NMJ

:   Neuromuscular junction

t~10~

:   Time-to-10% peak tension

t~inhib~

:   Time at which ≥10% of unbound BoNT/A is present and available for an inhibitor to exert some effect
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